Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced … Continue reading →

Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and … Continue reading →

As 2025 approaches, cancer continues to be one of the most significant global health challenges. Projections indicate a sharp increase in cancer diagnoses, with new cases in 2024 expected to surpass 2 million annually in the United States for the … Continue reading →

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted antitumor virotherapies, will host an investor webinar on Feb. 5, 2025, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature CFO Andrew Jackson and CSO Antonio … Continue reading →

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with gross proceeds expected to total approximately $4.25 million before fees and … Continue reading →

Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing the global cancer burden, innovation remains critical to achieving … Continue reading →